Evobrutinib drug interaction study completed in healthy volunteers
NCT ID NCT05064488
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed Phase 1 study tested how multiple doses of evobrutinib, an experimental drug, affect the way the body processes four common medications: digoxin, metformin, rosuvastatin, and sumatriptan. Forty healthy adults participated in two parts, receiving evobrutinib along with single doses of these drugs. The goal was to measure drug levels in the blood and check for side effects, helping to guide future use of evobrutinib.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Evobrutinib
What this could lead to
If successful, this study could help doctors understand how evobrutinib interacts with common medications, guiding safer use in future patients.
What could go wrong
This is an early-phase, drug-interaction study in healthy volunteers, not a treatment trial. Results may not predict effects in patients or lead to any new therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nuvisan GmbH
Neu-Ulm, 89231, Germany